Literature DB >> 9537501

Intravenous pamidronate treatment in osteogenesis imperfecta.

I Fujiwara, E Ogawa, Y Igarashi, M Ohba, A Asanuma.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9537501

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN： 0340-6199            Impact factor:   3.183


× No keyword cloud information.
  9 in total

1.  Responsiveness to pamidronate treatment is not related to the genotype of type I collagen in patients with osteogenesis imperfecta.

Authors:  Junko Kanno; Akiko Saito-Hakoda; Shigeo Kure; Ikuma Fujiwara
Journal:  J Bone Miner Metab       Date:  2017-05-20       Impact factor: 2.626

Review 2.  Systematic review of effectiveness of bisphosphonates in treatment of low bone mineral density and fragility fractures in juvenile idiopathic arthritis.

Authors:  J Thornton; D M Ashcroft; M Z Mughal; R A Elliott; T W O'Neill; D Symmons
Journal:  Arch Dis Child       Date:  2006-05-11       Impact factor: 3.791

Review 3.  Osteogenesis imperfecta: practical treatment guidelines.

Authors:  F Antoniazzi; M Mottes; P Fraschini; P C Brunelli; L Tatò
Journal:  Paediatr Drugs       Date:  2000 Nov-Dec       Impact factor: 3.022

4.  Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta.

Authors:  E Aström; S Söderhäll
Journal:  Arch Dis Child       Date:  2002-05       Impact factor: 3.791

5.  Pamidronate treatment of pediatric fracture patients on chronic steroid therapy.

Authors:  Philip D Acott; Jaime A Wong; Bianca A Lang; John F S Crocker
Journal:  Pediatr Nephrol       Date:  2005-02-03       Impact factor: 3.714

Review 6.  Osteogenesis imperfecta and therapeutics.

Authors:  Roy Morello
Journal:  Matrix Biol       Date:  2018-03-11       Impact factor: 11.583

7.  Pamidronate in a girl with chronic renal insufficiency dependent on parenteral nutrition.

Authors:  Janet L Duke; Deborah P Jones; Noel K Frizzell; Russell W Chesney; Emily B Hak
Journal:  Pediatr Nephrol       Date:  2003-05-15       Impact factor: 3.714

Review 8.  The role of bisphosphonates in diseases of childhood.

Authors:  Tarak Srivastava; Uri S Alon
Journal:  Eur J Pediatr       Date:  2003-09-11       Impact factor: 3.183

9.  Current and emerging treatments for the management of osteogenesis imperfecta.

Authors:  Elena Monti; Monica Mottes; Paolo Fraschini; Piercarlo Brunelli; Antonella Forlino; Giacomo Venturi; Francesco Doro; Silvia Perlini; Paolo Cavarzere; Franco Antoniazzi
Journal:  Ther Clin Risk Manag       Date:  2010-09-07       Impact factor: 2.423
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.